Form 4 for TLX Telix Pharmaceuticals Ltd
Accepted 2026-09-14 19:20:14 ET · period of report 2026-09-07 · accession 0001628280-26-061944 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 19:20 | 2026-09-07 | TLX | Smith Darren Charlton | Group CFO | P - Purchase | $9.66 | +2,071 | 14.0K | +17% | +$20.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-09-07 | P | A | 2,071 | $9.66 | 13,992 | D | — | — | (F1) Represents shares purchased by the Reporting Person under the Employee Share Purchase Plan section of the Issuer's Equity Incentive Plan ("AU ESPP"), which shares were allocated on September 7, 2026, based on the Reporting Person's contributions to the AU ESPP from January 1, 2026 - June 30, 2026. (F2) Purchase price is recorded in Australian Dollars. |